Menu Close

The Cipa Assay Test For Cardiomyopathy

The Cipa assay is a routine method of genetic analysis that has served to generate a lot of valuable data about genetic diseases. This genetic testing process uses a battery of DNA tests designed specifically to identify single nucleated cells that are either human in origin or not. While there are many uses for this technology, the most widely applied one is the Cipa assay for the purpose of genetic counselling. Cipa is also known as DNA probe test and it is performed by analysing a person’s DNA for matches to genetic abnormalities and health conditions. While this is the basic principle of the test, there are still a lot of benefits you can get from this kind of test, and here are some of them:

How Cipa Assay Can Be Used And Applied

* It identifies the defective genes – It was discovered that every person has fifty percent of abnormal genes, which may affect their health. The defective genes identified in this study are called the arrhythmogenic arrhythmias. These are actually the result of the failure of the cells to produce a chemical signal called the action potential. This chemical signal is needed for proper heart rhythm, and the abnormal gene prevents the cells from being able to do this properly. The Cipa assay can help determine whether the patient is suffering from arrhythmias caused by defective genes, or is suffering from other medical conditions affecting the ventricular myocytes (the myocardium) and the action potential.

* It can monitor genetic diseases – Patients with genetic diseases such as Prader-Willi Synddrome and Cystic Fibrosis have been found to have abnormal activity of the cardiac ion channels. The Cipa assay can be used to monitor the activity of these channels in patients, thereby helping in the diagnosis of the disorder. The results can also be compared to other normal controls to reveal potential arrhythmias caused by the genetic anomalies. This is very important in the field of cardiopulmonary surgery, wherein invasive procedures may lead to irreversible arrhythmias in patients who may not have shown any symptoms of the disorder.

* Nanomaterials in medical equipment’s – Nanomaterials have been proven to help medical devices perform better. When it comes to the use of Cipa, this method allows for the detection of abnormal electrical currents in the body. These currents often lead to heart attacks, which are fatal. Therefore, early detection and analysis can be crucial in order to ensure that someone’s health and overall wellbeing is well maintained and protected.


* Better clinical control – Using Cipa assay has led to better clinical control of patients with cardiopulmonary disorders. Patients are often monitored regularly with electrocardiograms, and blood pressures. This has made possible the earlier use of biofeedback and other alternative treatments for patients with heart failure. When using Cipa, regular laboratory testing is recommended for everyone to ensure safety. This allows for the early identification of abnormalities that could have been precursors to more serious diseases.

* Outcomes seen in animal trials – Although Cipa has been approved by the Food and Drug Administration, this does not mean it has been shown to work in humans. There have been no clinical trials involving humans, and only two clinical trials focused on Cipa efficacy and safety, focusing on cardioexcyte 96 and the pharmacogenetics of PRsychosomatic Treatment Resistance Strategies (PTRS). The goal of these studies was to determine whether cardioexcyte 96 and PTRS can achieve similar effects in patients with objective-restrained heart rhythms. Based on the study results, the working group studies determined that Cipa assay can possibly reduce abnormal heart rhythms, but not abnormal conduction and muscle tone.